• 1
    Singleton JW, Law DH, Kelley ML, et al. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 87082.
  • 2
    Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994; 331: 8425.
  • 3
    Löfberg R, Østergaard-Thomsen O, Langholtz E, et al. Budesonide versus prednisolone enema in active distal ulcerative colitis: a comparative eight week study. Gut 1993; 34 (Suppl. 1): S41(Abstract).
  • 4
    The Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis: a randomized dose–response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991; 26: 122530.
  • 5
    Thomsen O, Andersen T, Langholz E, et al. Lack of adrenal gland suppression with budesonide enema treatment in active distal ulcerative colitis: a prednisolone controlled eight week study. Gut 1993; 34(Suppl. 3): S27S27(Abstract).
  • 6
    Edsbäcker S, Wollmer P, Nilsson Å, Nilsson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology 1993; 104 (Suppl.): A695A695(Abstract).
  • 7
    Löfberg R, Danielsson Å, Salde L. Oral budesonide in active ileocaecal Crohn’s disease. Aliment Pharmacol Ther 1993; 7: 6116.
  • 8
    Brattsand RL. Steroid development: a case of enhanced selectivity for the bowel wall. Res Clin Forums 1993; 15(5): 1731.
  • 9
    Gustafsson B & Persson CGA. Allergen-induced mucosal exudation of plasma into rat ileum and its inhibition by budesonide. Scand J Gastroenterol 1992; 27: 58793.
  • 10
    Gustafsson B & Persson CGA. Oral budesonide exhibits greater topical selectivity than prednisolone in a rat ileal inflammation model. Gastroenterology 1994; 106(4): A696A696(Abstract).
  • 11
    Persson CGA, Gustafsson B, Erjefält JS, Sundler F. Mucosal exudation of plasma is a noninjurious intestinal defence mechanism. Allergy 1993; 48: 5816.
  • 12
    Cvetkovic S, Edsbäcker S, Ejerblad S, Ekman I, Kagedal M. Intraluminal concentrations of budesonide following administration of Entocort® capsules in subject with ileostomy. Gut 1997; 41(Suppl. 3): A222A222(Abstract).
  • 13
    Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 62330.
  • 14
    Persson CG, Erjefält JS, Greiff L, et al. Contribution of plasma-derived molecules to mucosal immune defence, disease, and repair. Scand J Immunol 1998; 47: 30213.DOI: 10.1046/j.1365-3083.1998.00317.x
  • 15
    Dahlberg E, Thalén A, Brattsand R, et al. Correlation between chemical structure, receptor binding and biological activity in some novel, highly active, 16α,17α-acetyl-substituted glucocorticoids. Mol Pharmacol 1984; 25: 708.
  • 16
    Andersson P, Appelgren LE, Ryrfeldt Å. Tissue distribution and fate of budesonide in the mouse. Acta Pharmacol Toxicol (Copenh) 1986; 59: 392402.
  • 17
    Campieri M, Ferguson A, Doe W, Persson T, Nilsson L-G, the Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Gut 1997; 41: 20914.
  • 18
    Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 25: 13117.
  • 19
    Thorsson L, Thunnisen FBJM, Korn S, Carlshaf A, Edsbäcker S, Wouters EFM. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med 1998; 153 (3): A404A404(Abstract).
  • 20
    Petersen H, Kullberg A, Edsbäcker S, Greiff L. Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo. Br J Clin Pharmacol 2001; 51: 15963.DOI: 10.1046/j.1365-2125.2001.01303.x
  • 21
    Brattsand R. What factors determine anti-inflammatory activity and selectivity of inhaled steroids? Eur Respir Rev 1997; 7(50): 35661.
  • 22
    Angus P, Snook JA, Reid M, Jewell DP. Oral fluticasone propionate in active distal ulcerative colitis. Gut 1992; 33: 7114.
  • 23
    Wright JP, Jarnum S, De-Muckadell OS, Keech ML, Lennard-Jones JE. Oral fluticasone propionate compared with prednisolone in treatment of active Crohn’s disease: a randomized double-blind multicentre study. Eur J Gastroenterol Hepatol 1993; 5/7: 499503.
  • 24
    Miller-Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162: 145561.